News & Press

follow us
into the future

Our platform, which combines oncRNA technology with AI, provides actionable insights into cancer biology.

Featured

Exai Bio Appoints Oncology Leader and Former American Cancer Society CEO, Karen E. Knudsen, MBA, PhD, to its Board of Directors

Exai Bio Appoints Oncology Leader and Former American Cancer Society CEO, Karen E. Knudsen, MBA, PhD, to its Board of Directors

Exai Bio Announces Publication in Nature Communications Highlighting its Generative AI Liquid Biopsy Platform

Exai Bio Appoints Dave Daly as Chief Executive Officer

Exai Bio to Present New Breast Cancer Data at the American Association for Cancer Research (AACR) 2024 Annual Meeting

Exai Bio’s RNA- and AI-based Liquid Biopsy Platform Detects Early Stage Breast Cancer with High Accuracy, Overcoming Many Limitations of DNA-based Approaches

Exai Bio Presents Data Further Validating its Liquid Biopsy Platform at the 2023 World Conference on Lung Cancer

Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting

Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai’s Novel RNA-based Liquid Biopsy Platform in Breast Cancer

Exai Bio Announces Appointments of Emi Zychlinsky and Seema Singh Bhan to its Executive Leadership Team

Exai Bio’s RNA-based Liquid Biopsy Platform Delivers Promising Data on Detecting Breast Cancer at its Earliest Stages

Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer

Exai Bio is presenting data from its scientific research program on the discovery and validation of tumor-specific, orphan non-coding RNAs.

Exai Bio Demonstrates its Unique RNA-based Liquid Biopsy Strategy for Early Detection and Monitoring of Multiple Cancers

Exai Bio announced it has raised a $67.5 million Series A financing to accelerate development of its non-invasive, RNA-based liquid biopsy platform.

Exai Bio Secures $67.5 Million Series A